Tseng L F, Collins K A
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee.
J Pharmacol Exp Ther. 1991 Oct;259(1):330-6.
Bremazocine, a benzomorphan, has been reported to have kappa, mu and epsilon opioid receptor binding activities. The present studies were then designed to determine what types of opioid receptors and neurotransmitters were involved in inhibiting the tail-flick response induced by bremazocine in male ICR mice. U50, 488H, a prototypic kappa agonist, was used for comparison. Bremazocine, at doses from 0.1 to 1 microgram given i.c.v., dose-dependently inhibited the tail-flick response. The paw-licking hot plate response, even at high doses of bremazocine, was not completely inhibited. The inhibition of the tail-flick response induced by bremazocine (1 microgram) given i.c.v. was blocked by i.c.v. coadministration of beta-endorphin-(1-27) (3 and 6 micrograms), an epsilon opioid receptor antagonist and norbinaltorphimine (4 micrograms), a kappa opioid receptor antagonist. On the other hand, the inhibition induced by i.c.v. U50,488H (40 micrograms) was blocked by i.c.v. norbinaltorphimine, but not beta-endorphin-(1-27). D-Phe-Cys-Tyr-D-Try-Orn-Thr-Pen-Thr-NH2 (CTOP; 0.5 microgram) and beta-funaltrexamine (beta-FNA; 2.5 micrograms), selective mu opioid receptor antagonists, and ICI 174,864 (10 micrograms), a delta-opioid receptor antagonist, which blocked the effects induced by DAMGO (16 ng) and DPDPE (20 micrograms), respectively, did not block inhibition of the tail-flick response induced by bremazocine (1 microgram) given i.c.v. The inhibition of the tail-flick response induced by i.t. administration of bremazocine (1 microgram) was blocked by i.t. coadministration of norbinaltorphimine but not CTOP, ICI 174,864, or beta-endorphin-(1-27).(ABSTRACT TRUNCATED AT 250 WORDS)
布马佐辛是一种苯并吗啡烷,据报道具有κ、μ和ε阿片受体结合活性。本研究旨在确定在雄性ICR小鼠中,布马佐辛抑制甩尾反应涉及何种类型的阿片受体和神经递质。使用原型κ激动剂U50,488H作为对照。脑室内注射剂量为0.1至1微克的布马佐辛,可剂量依赖性地抑制甩尾反应。即使在高剂量的布马佐辛作用下,舔爪热板反应也未被完全抑制。脑室内注射1微克布马佐辛所诱导的甩尾反应抑制作用,可被脑室内共同注射ε阿片受体拮抗剂β-内啡肽-(1-27)(3微克和微克)和κ阿片受体拮抗剂诺宾那托啡(4微克)所阻断。另一方面,脑室内注射40微克U50,488H所诱导的抑制作用,可被脑室内注射诺宾那托啡阻断,但不能被β-内啡肽-(1-27)阻断。选择性μ阿片受体拮抗剂D-苯丙氨酸-半胱氨酸-酪氨酸-D-色氨酸-鸟氨酸-苏氨酸-青霉胺-苏氨酸-NH2(CTOP;0.5微克)和β-芬太尼丁胺(β-FNA;2.5微克),以及δ阿片受体拮抗剂ICI 174,864(10微克),它们分别阻断了由DAMGO(16纳克)和DPDPE(20微克)所诱导的效应,但并未阻断脑室内注射1微克布马佐辛所诱导的甩尾反应抑制作用。脊髓内注射1微克布马佐辛所诱导的甩尾反应抑制作用,可被脊髓内共同注射诺宾那托啡阻断,但不能被CTOP、ICI 174,864或β-内啡肽-(1-27)阻断。(摘要截短于250字)